论文部分内容阅读
[目的]观察布拉氏酵母菌散剂对溃疡性结肠炎(UC)患者的临床疗效以及其相应的免疫调节作用。[方法]收集2012年7月~2015年6月黄石市中心医院消化内科诊治的UC患者72例,使用数字法随机分为美沙拉嗪治疗对照组(对照组)和美沙拉嗪+布拉氏酵母菌散剂治疗观察组(观察组),每组36例。IL-17、IL-10和IL-6表达使用ELISA法检测,比较2组的临床疗效和不良反应。[结果]2组患者治疗前肠镜充血水肿、糜烂、溃疡的检出率差异无统计学意义(P>0.05),治疗后2组充血水肿、糜烂、溃疡的检出率均出现显著减低(P<0.05和P<0.01),但治疗后观察组充血水肿、糜烂、溃疡的检出率显著低于对照组(P<0.05)。观察组临床治疗有效率为88.9%,显著高于对照组的72.2%(P<0.05)。2组患者治疗前IL-17、IL-10和IL-6表达水平差异无统计学意义(P>0.05),治疗后2组均出现IL-17、IL-6减低和IL-10升高(P<0.01),但观察组IL-17、IL-6减低的幅度以及IL-10升高的幅度显著大于对照组(P<0.05)。观察组不良反应发生率为13.9%,对照组不良反应发生率为11.1%,治疗期间2组临床不良反应发生率差异无统计学意义(P>0.05)。[结论]布拉氏酵母菌散剂可以显著减低UC患者IL-17表达和升高IL-10表达,抑制炎症反应,临床疗效显著、使用安全。
[Objective] To observe the clinical curative effect of Blast yeast powder on patients with ulcerative colitis (UC) and its corresponding immunoregulatory effects. [Methods] Seventy-two patients with UC who were treated in Department of Gastroenterology, Central Hospital of Huangshi from July 2012 to June 2015 were randomly divided into mesalazine treatment group (control group) and mesalazine + Brays yeast Bacterial powder treatment observation group (observation group), 36 cases in each group. The expression of IL-17, IL-10 and IL-6 were detected by ELISA. The clinical efficacy and adverse reactions of the two groups were compared. [Results] There was no significant difference in the incidence of colonoscopy congestion, edema, erosion and ulcer before treatment in both groups (P> 0.05). The detection rate of congestion, edema and ulcer were significantly decreased in both groups after treatment P <0.05 and P <0.01). However, the detection rate of congestion, edema and ulcer in the observation group was significantly lower than that of the control group after treatment (P <0.05). The effective rate of clinical treatment in observation group was 88.9%, which was significantly higher than that in control group (72.2%, P <0.05). The levels of IL-17, IL-10 and IL-6 in the two groups had no significant difference before treatment (P> 0.05), while the levels of IL-17, IL-6 and IL- P <0.01). However, the decrease of IL-17 and IL-6 and the increase of IL-10 in the observation group were significantly greater than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was 13.9%, and the incidence of adverse reactions in the control group was 11.1%. There was no significant difference in the incidence of adverse reactions between the two groups during the treatment (P> 0.05). [Conclusion] Bragg yeast powder can significantly reduce the expression of IL-17 in UC patients and increase the expression of IL-10, and suppress the inflammatory reaction. The clinical efficacy is significant and safe to use.